Sentence examples for aggregate cost to from inspiring English sources

And the $2 billion annual investment falls well short of the $6 billion invested each year in cancer and the $3 billion invested each year for HIV/AIDS -- two diseases which, though terrible, have far less aggregate cost to society.

The aggregate cost to Kenyan households of managing uncomplicated childhood fevers was at least $96 million in 2002, equivalent to 1.00% of the Kenyan GDP.

Considering the psychosocial consequences which may result from a stillbirth in isolation, Cacciatore suggests that the aggregate cost to society would be significant [ 45].

It also quantifies the aggregate cost to the state from lost taxation revenue, increased social welfare payments, and estimates the national GDP loss due to individuals exiting the labour force due to depression and other mental health conditions.

Assuming that the number of fevers in 2002 was essentially the same as 2005, and using the $1.92 cost per fever from Table 1, the aggregate cost to Kenyan households of managing uncomplicated childhood fevers was $96 million in 2002, representing a direct cost to the Kenyan economy equivalent to 1.00% of annual Kenyan gross 2002 national income.

The national aggregate cost to government due to early retirement from these conditions equated to $278 million £152.99 million) in lost income taxation revenue, $407 million £223.99 million) in additional transfer payments and around $1.7 billion in GDP in 2009 alone.

This method estimates procedure-level costs by computing an overall ratio of departmental aggregate costs to charges and applying this ratio for individual procedures and services.

At present, companies have to disclose perks to individuals in excess of $50,000, valued on the basis of their "aggregate incremental cost" to the company.

Since 1994, these two Brits and their company Working Title have sold $2 billion worth of tickets to films that in aggregate cost only $320 million to make.

In sensitivity analysis, we particularly focused on the role of screening volume, because this is a parameter of major uncertainty and, a priori, was likely to have a major impact on aggregate costs due to the potential for economies of scale at high volumes.

The analysis of the mean aggregate costs incurred to either death or a follow-up period of 5 years showed that patients experiencing a contralateral primary tumour or a locoregional recurrence incurred more costs than patients experiencing a distant recurrence without a prior contralateral or locoregional event.